Recurrent Glioblastoma Multiforme (GBM) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Glioblastoma (GBM) is the most aggressive primary malignancy of the central nervous system (CNS) in adults, with a median age of diagnosis of 65 years. In newly diagnosed GBMM, the standard of care includes maximally safe surgical resection, followed by concurrent radiotherapy and temozolomide (TMZ), and six-monthly cycles of adjuvant TMZ. Treatment options are limited when tumors progress after first-line therapy, and recurrent GBM (rGBM) management remains challenging. GBM recurrence is inevitable after a median survival time of 32–36 weeks due to a lack of uniform definition and criteria for tumor recurrence; institutional variability in treatment philosophy; and the heterogeneous nature of the disease, including the location of recurrence and distinct mechanisms believed to contribute to known subtypes of GBM. More than 90% of patients with glioma showed recurrence at the original tumor location, and that multiple lesions developed in 5% after treatment. Second, although less common, GBM may also recur by developing new parenchymal lesions that fail to exhibit continuous growth patterns, intraventricular spread, or dissemination.

 

The incidence of Glioblastoma (GBM) ranges from 2.8 to 3.2 cases per 100,000 population in the USA, among which 70 to 80% are recurrent cases.

 

The competitive landscape of Recurrent Glioblastoma Multiforme (GBM) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Recurrent Glioblastoma Multiforme (GBM) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Recurrent Glioblastoma Multiforme (GBM) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Recurrent Glioblastoma Multiforme (GBM) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Berubicin          CNS Pharmaceuticals    Phase 1

2          VXM01 Vaximm GmbH Phase 2

3          IORT    Xoft, Inc.           Phase 2

4          GX-I7   Genexine, Inc.  Phase 2

5          TTAC-0001       PharmAbcine    Phase 2

6          BAL101553       Basilea Pharmaceutica  Phase 2

7          Pemigatinib       Incyte Corporation         Phase 2

8          Carboplatin       InSightec          Phase 2

9          Sym004            Symphogen A/S            Phase 2

10        CYNK-001        Celularity Incorporated  Phase 2

Continued

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypoglycemia and severe
Read more